



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Abemaciclib metabolite M2

<b>Cat. No.:</b>	HY-128669		
<b>CAS No.:</b>	1231930-57-6		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>28</sub> F <sub>2</sub> N <sub>8</sub>		
<b>Molecular Weight:</b>	478.54		
<b>Target:</b>	CDK; Drug Metabolite		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 2 mg/mL (4.18 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.0897 mL	10.4484 mL	20.8969 mL
		5 mM	---	---	---
10 mM		---	---	---	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC <sub>50</sub> s of 1.2 and 1.3 nM, respectively. Anti-cancer activity <sup>[1][2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	CDK4 1.2 nM (IC <sub>50</sub> )	CDK6 1.3 nM (IC <sub>50</sub> )
<b>In Vivo</b>	Abemaciclib metabolite M2 (LSN2839567) is bound to plasma proteins in rat, dog and human (83-92%), lower than Abemaciclib (95-99%) <sup>[2]</sup> . Abemaciclib metabolite M2 is the most prominent (active and major) plasma metabolites in human <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

---

## CUSTOMER VALIDATION

- J Pharm Biomed Anal. 2022: 115211.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. CHMP. Assessment report Verzenios. 26 July 2018 EMA/551438/2018.
- [2]. Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA